HilleVax initiated with bullish view at H.C. Wainwright, here’s why

H.C. Wainwright initiated coverage of HilleVax with a Buy rating and $28 price target. HilleVax’s focus is on the development and commercialization of novel vaccine therapeutics with lead vaccine candidate HIL-214 prospectively representing the first vaccine for norovirus-related acute gastroenteritis, initially targeting the infant population, the analyst tells investors in a research note. The firm believes the intramuscular HIL-214 norovirus vaccine program can demonstrate successful Phase 2b NEST-IN1 effect specifically on the number of subjects with moderate-to-severe acute gastroenteritis associated with the most common norovirus genotypes.